Developing Innovative Treg Cell Therapies for Autoimmune Diseases
PIPELINE OVERVIEW
Developing a robust pipeline of Treg cell therapies with the potential to transform the treatment of autoimmune diseases.
Our programs target significant unmet medical needs, with a focus on both prevalent and challenging conditions.
PIPELINE: CD6/CTLA4
Targeting destructive and autoreactive T-cells along with bystander suppression of B-cells, macrophages, and neutrophils has the potential to arrest autoimmune destruction in indications like T1D, Dermatological and Neuroinflammatory Autoimmune diseases, and in Rheumatoid arthritis.
01
Our approach focuses on preserving beta-cell function and preventing or slowing disease progression, particularly in early stages of the disease.
Immuthera is advancing Treg cell therapies to address Type 1 Diabetes (T1D), a chronic autoimmune disease characterized by the destruction of insulin-producing beta cells in the pancreas
02
NEXT GENERATION T1D THERAPIES
Immuthera is also exploring next-generation approaches, including antigen-specific Tregs and immunomodulatory strategies, to develop even more targeted and effective treatments for T1D.
03
PIPELINE: NEUROINFLAMMATION
Immuthera is also developing Treg cell therapies to treat neuroinflammatory diseases.
Including Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS), debilitating conditions characterized by inflammation and damage to the nervous system
EXPANDING OUR PIPELINE
PUBLICATIONS